TRACON Pharmaceuticals Completes Initial Public Offering

San Diego – February 13, 2015 – Cooley advised TRACON Pharmaceuticals, Inc. on its initial public offering, as well as a concurrent private placement. TRACON is a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, age-related macular degeneration and fibrotic diseases. The company now trades on The NASDAQ Global Market under the symbol "TCON."

The Cooley corporate securities team was led by partners Charlie Kim and Sean Clayton and included associates Kristin VanderPas, Dani Nazemian and Terren O'Connor.

Support for the offering was provided by partners Natasha Leskovsek and Wendy Goldstein, special counsel Phil Mitchell and associate Jennifer Shanley (health care and life sciences regulatory); special counsel Laura McDaniels (compensation and benefits); and partner Susan Cooper Philpot (tax).

About Cooley LLP

Cooley's lawyers solve legal issues for entrepreneurs, investors, financial institutions and established companies. Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, often where innovation meets the law.

Cooley has 850 lawyers across 12 offices in the United States, China and Europe.

Related Contacts
Susan Cooper Philpot Partner, San Francisco
Charlie Kim Partner, San Diego
Sean Clayton Partner, San Diego
Natasha Leskovsek Partner, Washington, DC
Laura McDaniels Special Counsel, Palo Alto
Kristin VanderPas Partner, San Francisco
Terren O'Connor Associate, San Diego
Wendy Goldstein Partner, New York
Phil Mitchell Partner, New York
Dani Nazemian Associate, San Diego